In 2023, the sales of systemic hormonal preparations excluding sex hormones and insulins in Italy stood at approximately 492 million Euros. Forecasts indicate a steady but mild growth from 2024 to 2028, with sales expected to increase from 492.4 million Euros to 494.1 million Euros. The year-on-year growth rates are minimal, reflecting a market characterized by stability rather than expansion, with less than a 0.1% increase each year. The compound annual growth rate (CAGR) over the five-year forecast period is anticipated to be marginal, emphasizing a stagnant market.
Future trends to watch for include the impact of new hormonal therapies and regulatory changes on the market. Additionally, demographic shifts and changes in healthcare policies could influence demand and market dynamics. Monitoring innovation in drug delivery systems and competitive landscape developments will be crucial for understanding potential shifts in market trends.
